Initial Dose Tarlatamab–Associated Tumour Lysis Syndrome in Small Cell Lung Cancer: A Case Report
Respirology Case Reports · 2026-07 · 14 (7)
DOI: 10.1002/rcr2.70667 ↗Kurz gefasst
Fallbericht in der Zeitschrift Respirology Case Reports, online erschienen am 28.06.2026. Verfasst von Katsuhiko Shibata und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine Sano Kosei General Hospital Tochigi Japan. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Tumour lysis syndrome (TLS) in solid tumours is rare but may occur in small‐cell lung cancer (SCLC) with a high tumour burden. We report a case of fatal TLS following tarlatamab treatment for relapsed SCLC. A 61‐year‐old woman with limited‐stage SCLC developed recurrence with extensive liver metastases after chemoradiotherapy and durvalumab consolidation therapy. Owing to rapid disease progression, an initial 1‐mg step‐up dose of tarlatamab was administered as second‐line treatment. On Day 2, the patient developed mild cytokine release syndrome, which improved with dexamethasone. On Day 6, she suddenly developed respiratory failure and impaired consciousness. Laboratory findings, including elevated lactate dehydrogenase, potassium, phosphorus and uric acid levels with acute kidney injury, suggested TLS and she died later that day. This case demonstrates that tarlatamab can induce fatal TLS even after a single 1‐mg dose. Patients with SCLC with extensive liver metastases require careful monitoring and aggressive strategies for TLS prevention.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine Sano Kosei General Hospital Tochigi Japan.
- Division of Pulmonary Medicine, Department of Medicine Keio University School of Medicine Tokyo Japan.
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine National Defense Medical College Saitama Japan.
- Department of Infectious Diseases Keio University School of Medicine Tokyo Japan.
ORCID-Profile: Hiromu Tanaka
Zitieren
APA
Shibata, K., Tanaka, H., Arai, Y., Watanuki, Y., Kokubo, T., Watanabe, Y., Nakayama, S., Asami, T., & Inoue, T. (2026). Initial Dose Tarlatamab–Associated Tumour Lysis Syndrome in Small Cell Lung Cancer: A Case Report. Respirology Case Reports, 14(7). https://doi.org/10.1002/rcr2.70667
Vancouver
Shibata K, Tanaka H, Arai Y, Watanuki Y, Kokubo T, Watanabe Y, et al. Initial Dose Tarlatamab–Associated Tumour Lysis Syndrome in Small Cell Lung Cancer: A Case Report. Respirology Case Reports. 2026;14(7). doi:10.1002/rcr2.70667
BibTeX
@article{Shibata2026,
author = {Shibata, Katsuhiko and Tanaka, Hiromu and Arai, Yusuke and Watanuki, Yusuke and Kokubo, Takashi and Watanabe, Yo and Nakayama, Shingo and Asami, Takahiro and Inoue, Takashi},
title = {Initial Dose Tarlatamab–Associated Tumour Lysis Syndrome in Small Cell Lung Cancer: A Case Report},
journal = {Respirology Case Reports},
year = {2026},
volume = {14},
number = {7},
doi = {10.1002/rcr2.70667}
}
EUVIMED